.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,597,961

« Back to Dashboard

Claims for Patent: 4,597,961

Title: Transcutaneous application of nicotine
Abstract:Percutaneous administration of nicotine in a dose approximating the dose delivered by a variety of nicotine-containing products, such as cigarettes, cigars, snuff and chewing tobacco, is carried out using an occlusive pad. The nicotine is delivered so as to mimic the pharmacological effects of nicotine provided by the conventional use of tobacco, and a therapeutic function is achieved by reducing or eliminating the need for the tobacco product. A suitable transdermal application pad comprises a reservoir for liquid nicotine base to be affixed to the skin in a variety of places. Due to the high lipid solubility and resultant high skin permeability of nicotine, vehicles or solvents are not generally needed to enhance dermal absorption.
Inventor(s): Etscorn; Frank T. (Socorro, NM)
Assignee:
Application Number:06/694,047
Patent Claims: 1. A method of administering nicotine for the purpose of satisfying a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with products of combustion of tobacco, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate sufficient to satisfy said nicotine habit, said occlusive pad comprising a nicotine-impermeable backing and nicotine-permeable, porous, inert membrane, said nicotine impermeable backing and said nicotine-permeable membrane defining a cavity therebetween, said cavity containing liquid nicotine therein.

2. A method according to claim 1 wherein said nicotine is in the form of nicotine base without a solvent, vehicle or carrier.

3. A method according to claim 1 wherein said nicotine is in the form of nicotine base diluted with a pharmaceutically acceptable carrier, solvent or vehicle which reduces penetration of the nicotine base through the skin.

4. A method according to claim 1 wherein said nicotine is administered by application to the skin behind the ear.

5. A method according to claim 1 wherein said pad comprises 1-4 microliters of nicotine base.

6. A method according to claim 1 wherein said nicotine is transdermally administered at a dosage rate of 15-25 nanograms per liter of blood.

7. A method of administering nicotine for the purpose of satisfying a nicotine habit in accordance with claim 1, wherein said nicotine is transdermally administered to a patient physically addicted to nicotine.

8. A method of assisting a person to quit smoking, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at at a dosage rate approximately the same as provided when absorbing nicotine by smoking, said occlusive pad comprising a nicotine-impermeable backing and nicotine-permeable, porous, inert membrane, said nicotine-impermeable backing and said nicotine-permeable membrane defining a cavity therebetween, said cavity containing liquid nicotine therein.

9. A method according to claim 8 comprising carrying out a series of said transdermal administrations and interspercing said transdermal administrations with cigarettes to slowly extinguish the reinforcing properties of non-pharmacological factors.

10. A method according to claim 8 wherein said pad comprises 1-4 microliters of nicotine base.

11. A method according to claim 10 wherein said nicotine is in the form of nicotine base without a solvent, vehicle or carrier.

12. A method according to claim 10 wherein said nicotine is in the form of nicotine base diluted with a pharmaceutically acceptable carrier, solvent or vehicle which reduces penetration of the nicotine base through the skin.

13. A method according to claim 10 wherein said nicotine is administered by application to the skin behind the ear.

14. A method according to claim 8 wherein said nicotine is transdermally administered at a dosage level of 15-25 nanograms per liter of blood.

15. A method of administering nicotine for the purpose of satisfying a nicotine habit in accordance with claim 8, wherein said nicotine is transdermally administered to a patient physically addicted to nicotine.

16. A method of administering nicotine for the purpose of satisfying a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with products of combustion of tobacco, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate sufficient to satisfy said nicotine habit, said occlusive pad comprising a nicotine impermeable backing defining a cavity therein, and an absorbant material having absorbed nicotine therein, within said cavity.

17. A method according to claim 16 wherein said pad comprises 1-4 microliters of nicotine base.

18. A method of assisting a person to quit smoking, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate approximately the same as provided when absorbing nicotine by smoking, said occlusive pad comprising a nicotine impermeable backing defining a cavity therein, and an absorbant material having absorbed nicotine therein within said cavity.

19. A method according to claim 18 wherein said pad comprises 1-4 microliters of nicotine base.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc